Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910934 · ClinicalTrials.gov registry record · NA
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
A NA study, sponsored by PATH.
- Completed
- Registry status
- NA
- Development phase
- 3,915
- Enrollment target
NCT02910934: Completed NA study, sponsored by PATH.
NCT02910934 is a NA study that has completed, run by PATH. The registered enrollment target is 3,915 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (179% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910934, a NA study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,915 participants
- Enrollment target
Study Summary
This study aims to provide National Malaria Control Programs (NMCP), international donors and other key stakeholders with clear evidence on the impact and cost-effectiveness of using indoor residual spraying (IRS) with a non-pyrethroid insecticide in a high malaria transmission area that has universal long-lasting insecticidal net (LLIN) coverage. This is an interventional study with IRS serving as the research intervention. The district of Mopeia, in the province of Zambezia, Mozambique will be the study site. This is a high transmission area with a malaria parasite prevalence of 54% in children. The Ministry of Health distributed LLINs in Mopeia in 2014-2015. The NMCP through funding from President's Malaria Initiative Africa Indoor Residual Spraying Project (PMI-AIRS) was able to cover half a district with indoor residual spraying. A simplified census took place in mid-2016 to determine the number of children five years of age and under in the district and enumerate and map the households to assist in implementation. From the 115 villages/bairros existent in Mopeia, 86 clusters were randomized in a government randomization ceremony to either receive IRS with Actellic or maintain no IRS. The IRS was implemented through a partnership between the NMCP and PMI-AIRS according to standard operational and consent procedures. From each cluster, a cohort of 18 children five years of age and under will be followed monthly to assess malaria incidence at the community level in both IRS and non-IRS villages. There will be 774 children in the IRS villages and 774 children in the no-IRS villages (total cohort will be 1548). Additionally, the routine health centre reporting system will be strengthened to assess malaria incidence in children five years of age and under by passive case detection. Three cross sectional studies in April 2017, April 2018, and April 2019 will assess changes in net use, health seeking behaviour and malaria prevalence at the community level. Entomol
Primary Outcome
Incidence at health facility level by passive case detection (with enhanced surveillance and quality control) along with implementation costing data using an ingredients approach
Interventions
- OTHER Actellic CS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,915 participants |
| Start Date | 2017-01-10 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT02910934 record still lists
NCT02910934 is an interventional study that assigns participants to a tested intervention. Its 3,915 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (179% higher).
The record links to 0 conditions, and to 1 intervention - of which Actellic CS is the first listed.
NCT02910934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02910934 about?
NCT02910934 is a clinical study titled "Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique". This study aims to provide National Malaria Control Programs (NMCP), international donors and other key stakeholders with clear evidence on the impact and cost-effectiveness of using indoor residual spraying (IRS) with a non-pyrethroid insecticide in a high malaria transmission area that has univers...
What is the current status of trial NCT02910934?
This trial is currently completed. It is a NA study. The enrollment target is 3,915 participants. The study started on 2017-01-10. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02910934?
The interventions under investigation include: Actellic CS (OTHER).
Who is sponsoring clinical trial NCT02910934?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02910934's enrollment target sits among peer trials
3,915 36th of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI